MAP2K7 and neoplasm: The activation of SRC following MEK pathway inhibition was strongest in HCT116 cells in vitro, and this was also observed in vivo correlating with enhanced inhibition of HCT116 tumour growth upon trametinib and AZD0424 combination treatment relative to respective single‐agent treatment in vivo.